Trial Profile
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Aticaprant (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 11 Dec 2017 Status changed from recruiting to active, no longer recruiting.